Stock Watch: Novartis And The Changing Face Of Big Pharma
Are Multi-Blockbusters Endangered Beyond The Current Crop?
The sun shines over a sector with multi-blockbuster products in their prime. But clouds are looming, and highly innovative products that cannot replace the sales shortfalls could lead to a re-rating of the sector’s growth prospects.
